Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • alpacas (6)
  • doramectin (5)
  • female (2)
  • half life (2)
  • ivermectin (2)
  • jugular vein (1)
  • research (1)
  • sheep (2)
  • Sizes of these terms reflect their relevance to your search.

    The objective of this research was to evaluate comparative pharmacokinetics of doramectin in alpacas, after subcutaneous administration of 0.2 mg/kg dose. Six healthy adult alpacas, mean age of 5 years ± 1, (three female and three gelded males) of mean bodyweight of 62 kg ± 16 kg with an average body condition scored 2.8 ± 1 out of five, were used in this study. Serial blood samples were collected from the jugular vein before the administration until day 21 afterwards to establish the pharmacokinetics of doramectin after its subcutaneous administration at 0.2 mg/kg dose. The blood samples were analysed using high-performance liquid chromatography (HPLC), fluorescence detection method with precolumn derivatisation, validated for alpacas. The pharmacokinetic parameters were calculated using a noncompartmental model, and results showed Cmax (6.05 ± 5.34 ng/ml), Tmax (3.83 ± 2.48 days), AUC (62.12 ± 18.86 ng/ml × d), terminal half-life (6.2 ± 4.9 days) and MRT (11.56 ± 4.43 days). The results of this study showed that the Cmax and AUC were much lower than in cattle and sheep at the same dosage. Tmax remained similar to cattle and sheep. This study presents valuable information about pharmacokinetics of doramectin in alpacas, which can be utilised in its future efficacy studies. © 2019 John Wiley & Sons Ltd.


    Gordon Lye, Anthony Jacob, William Pomroy, Kevin Stafford, Preet Singh. Pharmacokinetics of subcutaneously administered doramectin in alpacas. Journal of veterinary pharmacology and therapeutics. 2020 Mar;43(2):123-128

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 31660626

    View Full Text